XML 65 R58.htm IDEA: XBRL DOCUMENT
v3.25.3

Collaboration and License Agreements - Additional Information (Details) - USD ($) shares in Millions |  | 1 Months Ended | 3 Months Ended | 9 Months Ended |  |
--- | --- | --- | --- | --- | --- | ---
Oct. 10, 2025 | Oct. 31, 2023 | Sep. 30, 2022 | Dec. 31, 2021 | Jun. 30, 2021 | Sep. 30, 2025 | Sep. 30, 2024 | Sep. 30, 2025 | Sep. 30, 2024 | Dec. 31, 2024 | Jun. 30, 2022
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |
Current portion of deferred revenue |  |  |  |  |  | $ 110,320,000 |  | $ 110,320,000 |  | $ 108,858,000 |
Long-term portion of deferred revenue |  |  |  |  |  | 10,160,000 |  | 10,160,000 |  | $ 33,218,000 |
Lilly Agreement |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |
Agreement description |  | In October 2023, the Company entered into a Transfer and Delegation Agreement, or the Lilly Agreement, with Eli Lilly and Company, or Lilly, pursuant to which Lilly acquired certain assets and other rights under the Company’s amended collaboration and license agreement, or the Verve Agreement, with Verve, including the Company’s opt-in rights to co-develop and co-commercialize Verve’s base editing programs for cardiovascular disease (see discussion below related to the Verve Agreement). The Company granted Lilly an exclusive sublicense to the Verve technology originally licensed to the Company under the Verve Agreement. Lilly also acquired the right to receive any future milestone or royalty payments payable by Verve under the Verve Agreement and the rights and obligations to designate representatives and participate on the joint steering committee with Verve. The Company received a $200.0 million nonrefundable upfront payment and is eligible to receive up to $350.0 million in potential future development-stage payments upon the completion of certain clinical, regulatory and alliance events, of which $25.0 million has been received through September 30, 2025. |  |  |  |  |  |  |  |  |
Collaboration agreement upfront payment received |  | $ 200,000,000 |  |  |  |  |  |  |  |  |
Collaboration agreement milestones payment received |  |  |  |  |  | 25,000,000 |  | 25,000,000 |  |  |
Collaboration agreement performance obligation revenue recognized |  |  |  |  |  | 0 |  | 0 |  |  |
Deferred revenue liability |  |  |  |  |  | 0 |  | 0 |  |  |
Lilly Agreement | Maximum |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |
Additional proceeds from potential future development-stage payments |  | $ 350,000,000 |  |  |  |  |  |  |  |  |
Pfizer |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |
Agreement description |  |  |  | In December 2021, the Company entered into a research collaboration agreement, or the Pfizer Agreement, with Pfizer Inc., or Pfizer, focused on the use of certain of the Company’s base editing technology to develop in vivo therapies for rare genetic diseases of the liver, muscle, and central nervous system. Under the terms of the Pfizer Agreement, the Company will conduct all research activities through development candidate selection for three base editing programs that target specific genes corresponding to specific diseases that are the subject of such programs. Pfizer will have exclusive rights to license each of the three programs at no additional cost, each an Opt-In Right, and will assume responsibility for subsequent development and commercialization. At the end of the Phase 1/2 clinical trials, the Company may elect to enter into a global co-development and co-commercialization agreement with Pfizer with respect to one program licensed under the collaboration for an option exercise fee equal to a percentage of the applicable development costs incurred by Pfizer, or the Participation Election. In the event the Company elects to exercise its Participation Election, upon the payment of its option exercise fee, Pfizer and the Company would share net profits as well as development and commercialization costs in a 65%/35% (Pfizer/Company) split for such program. The research collaboration is managed on an overall basis by a Joint Research Committee, or JRC, formed by an equal number of representatives from the Company and Pfizer. |  |  |  |  |  |  |
Collaboration arrangement, initial term |  |  |  | 4 years |  |  |  |  |  |  |
Collaboration arrangement, option to extend |  |  |  | The initial four year term of the collaboration extends through December 2025 with an option to extend for an additional year. |  |  |  |  |  |  |
Collaboration arrangement extension term description |  |  |  | extended for an additional year on a program-by-program basis |  |  |  |  |  |  |
Potential total consideration |  |  |  | $ 1,350,000,000 |  |  |  |  |  |  |
Collaboration agreement aggregate transaction price |  |  |  | 300,000,000 |  |  |  |  |  |  |
Nonrefundable upfront payment receivable |  |  |  | $ 300,000,000 |  |  |  |  |  |  |
Collaboration agreement performance obligation revenue recognized |  |  |  |  |  | 0 | $ 2,700,000 | 0 | $ 8,400,000 |  |
Earn-out payment period |  |  |  | 10 years |  |  |  |  |  |  |
Current portion of deferred revenue |  |  |  |  |  | 99,000,000 |  | 99,000,000 |  |  |
Long-term portion of deferred revenue |  |  |  |  |  | 10,200,000 |  | 10,200,000 |  |  |
Pfizer | Assigned to Company | Upon Participation Election |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |
Net profits as well as development and commercialization costs percentage |  |  |  | 35.00% |  |  |  |  |  |  |
Pfizer | Assigned to Pfizer | Upon Participation Election |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |
Net profits as well as development and commercialization costs percentage |  |  |  | 65.00% |  |  |  |  |  |  |
Pfizer | Maximum | Per Program |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |
Development regulatory and commercial milestones receivable |  |  |  | $ 350,000,000 |  |  |  |  |  |  |
Apellis Pharmaceuticals, Inc |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |
Agreement description |  |  |  |  | In June 2021, the Company entered into a research collaboration agreement, or the Apellis Agreement, with Apellis Pharmaceuticals, Inc., or Apellis, focused on the use of certain of the Company’s base editing technology to discover new treatments for complement system-driven diseases. Under the terms of the Apellis Agreement, the Company will conduct preclinical research on six base editing programs that target specific genes within the complement system in various organs, including the eye, liver, and brain. Apellis has an exclusive option to license any or all of the six programs, or in each case, an Opt-In Right, and collectively, the Opt-In Rights, and will assume responsibility for subsequent development. As of September 30, 2025, Apellis notified the Company of its decision to opt-in to one of the six base editing programs. As a result of Apellis' decision to opt-in to the program, the Company received a cash opt-in fee of $3.8 million which was recognized as revenue during the three months ended September 30, 2025. The Company may elect to enter into a 50-50 U.S. co-development and co-commercialization agreement with Apellis with respect to one program licensed under the collaboration. The collaboration is managed on an overall basis by an alliance steering committee formed by an equal number of representatives from the Company and Apellis. |  |  |  |  |  |
Collaboration arrangement, initial term |  |  |  |  | 5 years |  |  |  |  |  |
Collaboration agreement performance obligation revenue period for recognition |  |  |  |  | 5 years |  |  |  |  |  |
Collaboration agreement aggregate transaction price |  |  |  |  | $ 75,000,000 |  |  |  |  |  |
Collaboration agreement performance obligation revenue recognized |  |  |  |  |  | 7,600,000 | 8,500,000 | 19,300,000 | 16,700,000 |  |
Upfront fee receivable upon signing contract |  |  |  |  | $ 50,000,000 |  |  |  |  |  |
Collaboration agreement first anniversary amount receivable |  |  |  |  |  |  |  |  |  |  | $ 25,000,000
Current portion of deferred revenue |  |  |  |  |  | 11,300,000 |  | 11,300,000 |  |  |
Apellis Pharmaceuticals, Inc | Maximum |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |
Collaboration arrangement extension term |  |  |  |  | 2 years |  |  |  |  |  |
Orbital |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |
Agreement description |  |  | Under the terms of the Orbital Agreement, the Company collaborated with Orbital to advance nonviral delivery and ribonucleic acid, or RNA, technology by providing Orbital with certain proprietary materials, a non-exclusive research license to certain RNA technology and nonviral delivery technology controlled by the Company, and by performing research and development support services as outlined in a research plan. The Company also granted Orbital an exploitation license to certain RNA technology and nonviral delivery technology controlled by the Company. The exploitation license was exclusive in the fields of vaccines and certain protein therapeutics during the research term, and after the research term is nonexclusive in all fields other than gene editing and conditioning. The collaboration is managed on an overall basis by a Joint Steering Committee, or JSC, comprised of an equal number of representatives from the Company and Orbital. |  |  |  |  |  |  |  |
Common stock shares received at closing |  |  | 75 |  |  |  |  |  |  |  |
Collaboration agreement performance obligation revenue period for recognition |  |  | 3 years |  |  |  |  |  |  |  |
Collaboration agreement aggregate transaction price |  |  | $ 25,500,000 |  |  |  |  |  |  |  |
Collaboration agreement performance obligation revenue recognized |  |  |  |  |  | 2,100,000 | $ 2,100,000 | 6,400,000 | $ 6,400,000 |  |
Current portion of deferred revenue |  |  |  |  |  | 0 |  | $ 0 |  |  |
Orbital | Subsequent Event |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |
Percentage of fully-diluted ownership stake | 17.00% |  |  |  |  |  |  |  |  |  |
Orbital | Subsequent Event | Common Stock |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |
Equity shares held | 75 |  |  |  |  |  |  |  |  |  |
Orbital | Bristol Myers Squibb | Subsequent Event |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |
Payments to acquire businesses for cash | $ 1,500,000,000 |  |  |  |  |  |  |  |  |  |
Orbital | Research Plan |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |
Collaboration arrangement, initial term |  |  | 3 years |  |  |  |  |  |  |  |
opt-in fee | Apellis Pharmaceuticals, Inc |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |
Collaboration agreement performance obligation revenue recognized |  |  |  |  |  | 3,800,000 |  |  |  |  |
opt-in to one | Apellis Pharmaceuticals, Inc |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |
Collaboration agreement performance obligation revenue recognized |  |  |  |  |  | $ 3,800 |  |  |  |  |

X
- Definition The aggregate transaction price of a collaboration agreement. + References No definition available. + Details
Name: | beam_CollaborationAgreementAggregateTransactionPrice
Namespace Prefix: | beam_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The amount receivable on the one-year anniversary of the signing date of a collaboration agreement. + References No definition available. + Details
Name: | beam_CollaborationAgreementFirstAnniversaryAmountReceivable
Namespace Prefix: | beam_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The amount received, as of the balance sheet date, for satisfaction of performance obligations as part of a collaboration agreement. + References No definition available. + Details
Name: | beam_CollaborationAgreementMilestonesPaymentReceived
Namespace Prefix: | beam_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The period over which revenue is expected to be recognized as part of a collaboration agreement. + References No definition available. + Details
Name: | beam_CollaborationAgreementPerformanceObligationRevenuePeriodForRecognition
Namespace Prefix: | beam_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of revenue recognized during the period for satisfaction of performance obligations as part of a collaboration agreement. + References No definition available. + Details
Name: | beam_CollaborationAgreementPerformanceObligationRevenueRecognized
Namespace Prefix: | beam_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of upfront payment received as part of a collaboration agreement. + References No definition available. + Details
Name: | beam_CollaborationAgreementUpfrontPaymentReceived
Namespace Prefix: | beam_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Collaboration arrangement extension term. + References No definition available. + Details
Name: | beam_CollaborationArrangementExtensionTerm
Namespace Prefix: | beam_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition The description of the extension term of a collaboration arrangement. + References No definition available. + Details
Name: | beam_CollaborationArrangementExtensionTermDescription
Namespace Prefix: | beam_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Collaboration arrangement initial term. + References No definition available. + Details
Name: | beam_CollaborationArrangementInitialTerm
Namespace Prefix: | beam_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Collaboration arrangement, option to extend. + References No definition available. + Details
Name: | beam_CollaborationArrangementOptionToExtend
Namespace Prefix: | beam_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The number of shares of common stock received as part of a collaboration agreement. + References No definition available. + Details
Name: | beam_CollaborationCommonSharesReceived
Namespace Prefix: | beam_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition The amount of milestones the Company may be eligible to receive. + References No definition available. + Details
Name: | beam_DevelopmentRegulatoryAndCommercialMilestonesReceivable
Namespace Prefix: | beam_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Earn-out payment period. + References No definition available. + Details
Name: | beam_EarnoutPaymentPeriod
Namespace Prefix: | beam_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition The number of shares of equity securities held by the Company. + References No definition available. + Details
Name: | beam_EquitySharesHeld
Namespace Prefix: | beam_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition The percentage of net profits and development and commercialization costs assigned to the specified party. + References No definition available. + Details
Name: | beam_NetProfitsAndDevelopmentAndCommercializationCostsPercentage
Namespace Prefix: | beam_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Nonrefundable upfront payment receivable. + References No definition available. + Details
Name: | beam_NonrefundableUpfrontPaymentReceivable
Namespace Prefix: | beam_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The amount of additional proceeds the Company may be eligible to receive as part of a transfer agreement. + References No definition available. + Details
Name: | beam_PotentialAdditionalProceedsFromTransferAgreement
Namespace Prefix: | beam_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Potential aggregate consideration that may be received as part of a collaboration agreement. + References No definition available. + Details
Name: | beam_PotentialConsideration
Namespace Prefix: | beam_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The amount of upfront fee receivable upon signing of a collaboration agreement. + References No definition available. + Details
Name: | beam_UpfrontFeeReceivableUponSigningContract
Namespace Prefix: | beam_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Description of nature and purpose of collaborative arrangements. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details
Name: | us-gaap_CollaborativeArrangementNatureAndPurpose
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-11 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2 + Details
Name: | us-gaap_ContractWithCustomerLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-11 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2 + Details
Name: | us-gaap_ContractWithCustomerLiabilityCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-11 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2 + Details
Name: | us-gaap_ContractWithCustomerLiabilityNoncurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3 + Details
Name: | us-gaap_EquityMethodInvestmentOwnershipPercentage
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 805 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479328/805-10-50-8 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 805 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 41 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479303/805-10-55-41 Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479581/805-30-50-2 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details
Name: | us-gaap_PaymentsToAcquireBusinessesGross
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=beam_LillyAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=beam_PfizerMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=beam_AssignedToCompanyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementScenarioAxis=beam_UponParticipationElectionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=beam_AssignedToPfizerMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=beam_PerProgramMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=beam_ApellisPharmaceuticalsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=beam_OrbitalTherapeuticsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=beam_BristolMyersSquibbMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=beam_ResearchPlanMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=beam_Opt-InFeeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=beam_Opt-InToOneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |